Why is NRXP down?
Down 4.4% on Nov 2, and still 4% under its Oct 30 close.
- It reported a press release in an SEC filing that day.
−2Long-term trend
Down 4.4% on Nov 2, and still 4% under its Oct 30 close.
−2Long-term trend
NRXP's Quality Score rose 1 point on Fri, Nov 13, to -6. It had its calmest day in a week.
Follow NRXP's trial news. Pro members can get an alert when NRX Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | 109.9% more shares than a year ago |
| Latest filing | 8-K, Oct 5 |
ReportReports today, after the close. Every 3 months, a company tells everyone how much it sold and earned. It rose after 2 of its last 3 reports, +6.7% on average. Past reports ›
Tue Nov 17: Q3 2026 Earnings Conference CallDate confirmed.
1 more date ahead: the meeting, for Pro members.
After its last 3 reports it closed +6.7% on average, higher 2 of 3 times.
About 5 quarters
No open-market buys or sales by its officers or directors in their filings of the last year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
NRXP is #218 of 270 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 218 |
Net income over four quarters: NRXP -$23.5M, INO -$71.1M.
Reports Mon Nov 16, after the close (today). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The change was primarily driven by certain research and development costs related to the acquisition of certain assets which management believes will drive significant long-term value for shareholders, as well as increased selling, general and administrative costs including, but not limited to, the addition of key personnel and other expenses related to the Company's anticipated commercial launch of its ANDA for preservative-free ketamine.”
NRXP's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Aug 17, 2026 | -5.2% | +4.9% | +8.9% |
| May 18, 2026 | +3.4% | -5.0% | -1.8% |
| Mar 24, 2026 | +6.8% | +20.3% | +18.1% |
Sales grew in 2025, to $1.2M. It lost money in both years.
RSI 37.0, MACD above signal, below both averages. Not scored.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
NRXP scores -6 today, which Breakaway calls Poor. It is #218 of 270 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 4.4% on Nov 2, and still 4% under its Oct 30 close. Cash lasts about 5 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
NRXP scores -6 today, which Breakaway calls Poor (below zero). That is #218 of 270 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind NRXP's -6.
Reports Mon Nov 16, after the close, a date the company confirmed. NRXP closed higher after 2 of its last 3 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.